GT
KRYS icon

Glenmede Trust’s Krystal Biotech KRYS Stock Holding History

Glenmede Trust’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$325K Buy
+874
New +$261K ﹤0.01% 1147

Other funds holding KRYS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Glenmede Trust's KRYS Position: Q2 2026 in Review

Glenmede Trust opened a new position in Krystal Biotech (KRYS) in Q2 2026: 874 shares worth $325K. The stake represents ﹤0.01% of the portfolio and ranks #1147 among its holdings.

422 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Glenmede Trust held 874 shares of Krystal Biotech worth $325K as of Q2 2026.
  • Krystal Biotech was a new Glenmede Trust position in Q2 2026.
  • Krystal Biotech made up ﹤0.01% of Glenmede Trust's portfolio in Q2 2026, its #1147 holding.
  • 422 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Glenmede Trust's 13F filing for Q2 2026, filed 10 Aug 2026.